Memphasys Ltd Reports Record Quarterly Revenue and Expands Global Footprint
Key points
- Record quarterly revenue of $150,000, up 34% from the previous quarter
- Largest-ever supply agreement with Monash IVF Group covering 22 Australian clinics
- Accelerated UK market entry with four IVF groups commencing commercial trials
- First entry into Southeast Asia with agreements in Vietnam and Thailand
- Regulatory approvals expected in Vietnam, Turkey, and India in the September 2026 quarter
Full summary
Memphasys Ltd reported a significant increase in quarterly revenue to $150,000, marking a 34% rise from the previous quarter. The company executed its largest commercial agreement with Monash IVF Group, covering its network of 22 Australian clinics. Memphasys also accelerated its entry into the UK market, with four IVF groups initiating commercial trials. Additionally, the company entered the Southeast Asian market for the first time, with agreements in Vietnam and Thailand. Regulatory approvals in Vietnam, Turkey, and India are expected in the September 2026 quarter, which will activate existing commercial agreements and support further sales growth. The company's cash on hand increased to $1.179 million, providing approximately 2.8 quarters of funding at the current operating cash outflow rate.
Guidance
Memphasys Ltd expects regulatory approvals in Vietnam, Turkey, and India in the September 2026 quarter.
Outlook
Memphasys Ltd enters FY27 with its broadest-ever commercial footprint, anchored by the largest supply agreement with Monash IVF Group, accelerated UK market entry, and new agreements in Southeast Asia. The company aims to complete the initial Monash IVF Group rollout phase, grow contracted clients in Europe and the UK, and leverage new inventory and operations management platform to support global commercial activity.
Summary generated by a large language model. Please interpret with care.